Biomarkers as Predictors of Recurrence following Curative Resection for Pancreatic Ductal Adenocarcinoma: A Review

Osayi, Sylvester N.; Bloomston, Mark; Schmidt, C. Max; Ellison, E. Christopher; Muscarella, Peter

doi:10.1155/2014/468959

Cited by 16 publications

(9 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,9 In a subset of PC nodes ( n = 14), miRNA-10b was increased by >1.5-fold ( p < 0.05), but in the other PC nodes ( n = 16), it did not differ from chronic pancreatitis ( p = 0.795) (Fig. 1a).…”

Section: Resultsmentioning

confidence: 98%

See 1 more Smart Citation

MicroRNA Expression in a Readily Accessible Common Hepatic Artery Lymph Node Predicts Time to Pancreatic Cancer Recurrence Postresection

Nguyen

Gore

Zhong

et al. 2016

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

Lymph node involvement in pancreatic adenocarcinoma (PAC) predicts postresection survival, but early lymph node metastasis detection is not easily accomplished. We assessed a panel of microRNAs (miRNAs) in a common hepatic artery lymph node (station 8) that is readily accessible during pancreatoduodenectomy (PD) to determine if increased miRNA levels correlate with postresection recurrence. Station 8 lymph nodes overlying the common hepatic artery collected during PD were assayed for miRNA-10b, miRNA-30c, miRNA-21, and miRNA-155 and cytokeratin-19 (CK19), an epithelial cell marker, using quantitative PCR. Expression was correlated with disease recurrence, recurrence-free survival (RFS), and overall survival (OS). Station 8 lymph nodes from 37 patients (30 periampullary carcinomas (PCs), 2 chronic pancreatitis, 5 other cancers) exhibited increased miRNA-10b levels in 14/30 PCs, and in 10 of these 14 patients, cancer recurred during the study period (2012–2015). High miRNA-10b was also associated with shorter RFS (42.5 vs. 92.4 weeks, p < 0.05) but not OS, whereas miRNA-30c, miRNA-21, and miRNA-155 levels and CK19 mRNA levels in station 8 nodes were variable and did not correlate with RFS or OS. We conclude that elevated miRNA-10b levels in station 8 lymph nodes could be utilized to assess risk for early disease progression in patients with periampullary tumors.

show abstract

Section: Resultsmentioning

confidence: 98%

“…However, the preoperative diagnostic and prognostic capability of CA19-9 is restricted due to marginal sensitivity and specificity and falsely elevated readings in the setting of biliary obstruction. 6,7 Other studies have attempted to identify additional tumor markers but none has proven to be superior to CA 19-9.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA Expression in a Readily Accessible Common Hepatic Artery Lymph Node Predicts Time to Pancreatic Cancer Recurrence Postresection

Nguyen

Gore

Zhong

et al. 2016

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

show abstract

“…Application of NMR (nuclear magnetic resonance) for mentioned indication is also wider for its ability to display outlet systems, which is beneficial. PET (positron emission tomography) CT is not applied as standard method in case of primary examination; its benefit is seen at the time of dispensarization (www.pathologyoutlines.com/pancreas.html; Hruban et al, 2000;Go et al, 2005;Delpu et al, 2011;Bockhorn et al, 2014;Diener et al, 2014;Edderkaoui and Eibl, 2014;Krška, 2014b;Osayi et al, 2014;Strobel and Büchler, 2014).…”

Section: Diagnostics -Imaging Methodsmentioning

confidence: 99%

“…Current ISGPS (International Study Group of Pancreatic Surgery) criteria for locally advanced tumour resectability are: (Hruban et al, 2000;Kelsen et al, 2008;Delpu et al, 2011;Bockhorn et al, 2014;Diener et al, 2014;Edderkaoui and Eibl, 2014;Krška, 2014a;Osayi et al, 2014).…”

Section: Tactics and Extent Of Surgical Proceduresmentioning

confidence: 99%

Pancreatic Cancer Diagnostics and Treatment – Current State

et al. 2015

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) represents permanent and ever rising issue worldwide. Five-year survival does not exceed 3 to 6%, i.e. the worst result among solid tumours. The article evaluates the current state of PDAC diagnostics and treatment specifying also development and trends. Percentage of non-resectable tumours due to locally advanced or metastatic condition varies 60-80%, mostly over 80%. Survival with non-resectable PDAC is 4 to 8 months (median 3.5). In contrast R0 resection shows the survival 18-27 months. Laboratory and imaging screening methods are not indicated on large scale. Risk factors are smoking, alcohol abuse, chronic pancreatitis, diabetes mellitus. Genetic background in most PDAC has not been detected yet. Some genes connected with high risk of PDAC (e.g. BRCA2, PALB2) have been identified as significant and highly penetrative, but link between PDAC and these genes can be seen only in 10-20%. This article surveys perspective oncogenes, tumour suppressor genes, microRNA. Albeit CT is still favoured over other imaging methods, involvement of NMR rises. Surgery prefers the "vessel first" approach, which proves to be justified especially in R0 resection. According to EBM immunotherapy same as radiotherapy are not significant in PDAC treatment. Chemotherapy shows limited importance in conversion treatment of locally advanced or borderline tumours or in case of metastatic spread. Unified procedures cannot be defined due to inhomogenous arrays. Surgical resection is the only chance for curative treatment of PDAC and depends mainly on timely indication for surgery and quality of multidisciplinary team in a high-volume centre.

show abstract

“…Even for the group of patients with local, resectable PDAC, the 5-year overall survival is just 20% [3]. The majority of patients who underwent radical surgery develop early recurrence within 12-18 months [4]. Reasons for the poor prognosis of this neoplasia are manifold: absence of specific symptoms during development, resulting in late diagnosis; high metastatic potential; resistance to chemotherapy/radiotherapy and the absence of reliable biomarkers for population screening.…”

mentioning

confidence: 99%

Recent advances in proteomically subtyping pancreatic ductal adenocarcinomas and their potential clinical impact

Roesli

2014

Expert Review of Proteomics

View full text Add to dashboard Cite

Biomarkers as Predictors of Recurrence following Curative Resection for Pancreatic Ductal Adenocarcinoma: A Review

Cited by 16 publications

References 71 publications

MicroRNA Expression in a Readily Accessible Common Hepatic Artery Lymph Node Predicts Time to Pancreatic Cancer Recurrence Postresection

MicroRNA Expression in a Readily Accessible Common Hepatic Artery Lymph Node Predicts Time to Pancreatic Cancer Recurrence Postresection

Pancreatic Cancer Diagnostics and Treatment – Current State

Recent advances in proteomically subtyping pancreatic ductal adenocarcinomas and their potential clinical impact

Contact Info

Product

Resources

About